Category Archives: Cell Biology

Cell Biology

Shanghai Cell Therapy Group Launches Collaboration with USC researcher to Improve the ex vivo Expansion of Hematopoietic Stem Cells for Clinical…

SHANGHAI, May27, 2020 /PRNewswire/ -- Shanghai Cell Therapy Group (SHCell) recently entered intoa six-year research collaborative project with Professor Qi-Long Ying from the University of Southern California (USC). Through the project, sponsored by $3.6 million from the Baize Plan Fund, the Ying laboratory aims to develop conditions for the long-term ex vivo expansion of mouse and human hematopoietic stem and progenitor cells.

"Hematopoietic stem cells, or HSCs, are found in the bone marrow of adults," said Professor Qijun Qian, CEO of Shanghai Cell Therapy Group. "HSCs have the ability for long-term self-renewal and differentiation into various types of mature blood cells, and for rebuilding normal hematopoiesis and immune function in patients. They also have enormous potential to treat diseases, including tumors, autoimmune diseases, severe infectious disease, and inherited blood diseases, and to combat the effects of aging."

This research project will be conducted and supervised by Professor Qi-Long Ying, a Professor of Stem Cell Biology and Regenerative Medicine at the Keck School of Medicine of USC. Professor Ying's pioneering stem cell research has won international acclaim, including the 2016 McEwen Award for Innovation, the highest honor in the field.

"We'll develop and optimize culture conditions for the long-term ex vivo expansion of HSCs," said Professor Ying. "We'll also test combinations of basal media, small molecules, cytokines and growth factors, and characterize ex vivo expanded hematopoietic stem and progenitor cells. These cells will then be genetically modified and tested for their potential to treat different diseases, including blood disorders and cancers."

Professor Andrew P. McMahon, Director of Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research of USC, added: "Stem cell biology represents an exciting area in medicine with great therapeutic potential. I am delighted SHCell is supporting Professor Ying. A breakthrough in the ability to propagate and manipulate HSCs will have lasting clinical significance."

The project also plans to build animal models of different blood diseases and cancers and test the safety and effectiveness of genetically modified hematopoietic stem and progenitor cells before clinical translation. SHCell will actively explore clinical applications of hematopoietic stem and progenitor cells in the treatment of cancers or blood diseases.

As SHCell's first overseas collaboration, this project aims to advance the goals of the Baize Plan: to provide first-class cell treatments and cell therapies at an affordable price to cure cancer and increase life expectancy. SHCell hopes that this project will also accelerate original scientific breakthroughs in the stem cell field.

Shanghai Cell Therapy Group

Founded in 2013, Shanghai Cell Therapeutics Group Co., Ltd is located at the Shanghai Municipal Engineering and Technology Research Center, which was established by the Shanghai Science and Technology Commission. With a mission of "changing the length and abundance of life with cell therapy", SHCell has created a closed-loop industrial chain and an integrated platform for cell treatment and cell therapy. It comprises cell storage, cell drug research and cell clinical transformation with cell therapy as its core business.

The Baize Plan was proposed in 2016 by Wu Mengchao, an Academician of the Chinese Academy of Sciences (CAS) and initiated by Professor Qian, aiming to provide first-class cell treatments and cell therapies at an affordable price with the goal of curing cancers and increasing life expectancy. The Baize Plan Fund was created by the Shanghai Cell Therapy Group to realize the vision of the Baize Plan.

University of Southern California (USC)

Founded in 1880, the University of Southern California is one of the world's leading educational and research institutions, and also the oldest private research university in California. Located in the heart of Los Angeles, the University of Southern California comprises 23 schools and units, and students are encouraged to explore different fields of study. The University of Southern California ranked #22 in National Universities in the 2020 edition of Best Colleges, published by U.S. News & World Report.

For more information, visit http://www.shcell.com/

See original here:
Shanghai Cell Therapy Group Launches Collaboration with USC researcher to Improve the ex vivo Expansion of Hematopoietic Stem Cells for Clinical...

Cell Biology

Alpacas and antibodies: How scientists hope to stop coronavirus in its tracks – Horizon magazine

Researchers at the Karolinska Institute in Stockholm, Sweden, are optimistic that at least one of the 124 vaccines in the pipeline will succeed. However, a vaccine needs to be delivered to everyone, and scaling to more than 7 billion doses is extremely challenging. So they have set their research sights on a more accessible goal: neutralising antibodies that kill an infection after it has taken hold.

The project CoroNAb was established in mid-February when there were 1,000 known deaths from Covid-19 in the world. Containing the spread of the virus is not our primary objective that ship has sailed, said Dr Benjamin Murrell, assistant professor at the Department of Microbiology, Tumor and Cell Biology at the Karolinska Institute. Our aim is to find therapeutics to stop the progression of disease within a patient.

Therapeutics

These therapeutics will take the form of antibodies that are infused into a patient through a syringe. When someone is infected with the new SARS-CoV-2 coronavirus, they typically mount an antibody response against it, and in most cases these antibodies contribute to clearing the virus. However, infection-fighting antibodies produced in a lab can also be introduced into the body, resulting in passive immunisation.

So what differentiates a vaccine from imported antibodies?

Vaccines are given to people when they are well, prompting them to develop their own antibodies, whereas antibody therapy is administered when an infection has taken hold and a patient is struggling to mount their own immune response.

Monoclonal antibodies (mAbs) that is, antibodies that are identical clones of one another have emerged over the past few decades as effective therapies for various medical conditions, including cancers and autoimmune disorders. Increasingly, they are also considered a major medical tool to fight severe viral infections such as Covid-19 though to date, only one mAb been approved for this purpose. Many more are in clinical trials, including one that Dr Murrell has been working on.

At what stage of an infection, exactly, a coronavirus patient would be treated with mAbs remains to be seen. This will need to be studied in animal models, or directly in human trials, said Dr Murrell, who is coordinating the CoroNAb project together with partners in Denmark, Switzerland, and the UK.

Maybe you can treat someone with monoclonal antibody therapy late in infection and still stop deterioration, but perhaps not, he said.

The CoroNAb team at the Karolinska Institute is creating mAbs from animals. An animal is given a specific viral antigen (the molecules that interact with a bodys antibodies) and an immune response is provoked, leading to some of the animals immune cells producing antibodies. The cells harbouring these antibodies are then isolated and the genetic sequence of the antibody is cloned from each cell into a circular form of DNA that allows the antibodies to be produced in the lab.

Since the potency of the antibodies discovered is at least partly down to chance, it makes sense for many groups to be going after the same goal.

Dr Benjamin Murrell, Karolinska Institute in Stockholm, Sweden

Alpacas

The Stockholm team is focusing its research efforts on mice, rhesus macaques and alpacas. Alpacas are camelids (like camels and llamas) producing particularly interesting antibody fragments, known as single domain antibodies, which allow for fast antibody discovery and large-scale antibody production, which is why they are favoured by the CoroNAb team.

One month into the project, these mammals have been injected with lab-created variants of the coronaviruss spike proteins, and preliminary indications suggest that all animal groups are responding well. Mining the alpaca antibody repertoire is currently underway. Over the next few weeks, the researchers will be testing the neutralising activity of the produced antibodies against SARS-CoV-2.

Dr Murrell said: The coming weeks are both critical and uncertain. Depending on these first results, well either get lucky, or we might have to take a few steps back and repeat.

Despite all the unknowns, Dr Murrell is confident that neutralising antibodies will emerge from this research. We will make something work, he said. The question is, will an effective antibody discovered by the CoroNAb team become a useful addition to Europes arsenal of SARS-CoV-2 treatments? Labs around the world are chasing the same prize, working night and day to identify effective antibodies against Covid-19, with some early results already emerging.

To make a contribution in this climate, an antibody will need to have a strong edge over its competition. If one groups antibody turns out to be 10 times more potent than the next best, you might have to produce far less of it for an effective therapy, reducing the manufacturing burden, explained Dr Murrell. He added, Since the potency of the antibodies discovered is at least partly down to chance, it makes sense for many groups to be going after the same goal.

Bacterium

Professor Luis Serrano from the Centre for Genomic Regulation (CRG) in Spain leads another team engaged in the race against Covid-19. His lab is both supporting global vaccine efforts and probing novel, non-vaccine mechanisms to limit the death toll.

Until two months ago, Prof. Serrano was engaged in the MycoSynVac project, which investigated ways to enlist cellular hosts to transport vaccines around the body. Cellular hosts (known in the field of synthetic biology as chassis) hold great promise as low-cost, scalable and potentially game-changing systems for the targeted delivery of life-saving vaccines.

The chosen chassis in Serranos five-year project was a modified form of the bacterium Mycoplasma pneumoniae, which causes respiratory infections. By the projects conclusion, the researchers were able to show that Mycoplasma makes an excellent universal chassis meaning all manner of vaccines can safely hitch a ride off it.

Prof. Serrano is optimistic that a vaccine for Covid-19, when it arises, will be among the ingredients that can be safely delivered by his Mycoplasma chassis. The team is in the early stages of testing this hypothesis. Over the next month or so, they will insert synthetic copies of key coronavirus genes into bacterial cells, in the hope that those surface proteins belonging to the virus will trigger a protective immune response from the human body.

As it is engineered from a bacterium that targets the lungs, the chassis may be capable of even more than vaccine transportation, according to Prof. Serrano. We think it can deliver therapeutic molecules directly to receptors in the lungs, he said.

These molecules would either counteract inflammation or stop the virus from binding to the alveoli (the cells through which oxygen flows from lungs to bloodstream) by blocking the viral cell receptors, he explains.

With the virus blocked or lung damage repaired, a patient who is not responding to conventional treatments might be spared the worst symptoms of a Covid-19 infection, such as a devastating cytokine storm, where the body mounts a massive, and potentially deadly, immune response an overreaction triggered by pneumonia.

Spray

The idea is to create a spray to deliver our engineered bacteria directly to the lungs, where it will express locally what is needed the active molecules and later it will be washed away naturally, explained Prof. Serrano.

He added: There are clear advantages to this direct approach. If you apply a drug systemically (affecting the whole body), it might be beneficial where its needed but it might also have dangerous effects on other tissue.

Price is another major benefit to recruiting bacteria to deliver life-saving medications. Producing therapeutic molecules synthetically is expensive. For a fraction of the cost, a host cell can be cloned to produce vast populations of cells containing the same therapeutic molecules.

In the labs of their spin-off company Pulmobiotics, Prof. Serranos team is exposing coronavirus proteins to molecules with known anti-inflammatory qualities, to test the molecules effectiveness against the virus. They are also engineering mutations of these molecules, hoping to increase the affinity between molecule and human receptor proteins. Data from these experiments is expected by mid-summer.

Prof Serrano is hopeful that his research will yield positive results, however these may not come in time to save lives during the current outbreak. By the time we get (regulatory) approval, the Covid situation may have been resolved, he said. But this research will open the way for future therapies during future pandemics.

The research in this article was funded by the EU. If you liked this article, please consider sharing it on social media.

Read more:
Alpacas and antibodies: How scientists hope to stop coronavirus in its tracks - Horizon magazine

Cell Biology

Research at MDI Biological Laboratory explores novel pathways of regeneration and tumorigenesis – Bangor Daily News

BAR HARBOR Research by scientists at the MDI Biological Laboratoryis opening up new approaches to promoting tissue regeneration in organs damaged by disease or injury.

In recent years, research in regenerative biology has focused on stem cell therapies that reprogram the bodys own cells to replace damaged tissue, which is a complicated process because it involves turning genes in the cells nucleus on and off.

A recent paper in the journal Genetics by MDI Biological Laboratory scientist Elisabeth Marnik, Ph.D., a postdoctoral fellow in the laboratory of Dustin Updike, Ph.D., offers insight into an alternate pathway to regeneration: by recreating the properties of germ cells.

Germ cells, which are the precursors to the sperm and egg, are considered immortal because they are the only cells in the body with the potential to create an entirely new organism. The stem cell-like ability of germ cells to turn into any type of cell is called totipotency.

By getting a handle on what makes germ cells totipotent, we can promote regeneration by unlocking the stem cell-like properties of other cell types, said Updike. Our research shows that such cells can be reprogrammed by manipulating their cytoplasmic composition and chemistry, which would seem to be safer and easier than changing the DNA within a cells nucleus.

Using the tiny, soil-dwelling nematode worm, C. elegans, as a model, the Updike lab studies organelles called germ granules that reside in the cytoplasm (the contents of the cell outside of the nucleus) of germ cells. These organelles, which are conserved from nematodes to humans, are one of the keys to the remarkable attributes of germ cells, including the ability to differentiate into other types of cells.

In their recent paper entitled Germline Maintenance Through the Multifaceted Activities of GLH/Vasa in Caenorhabditis elegans P Granules, Updike and his team describe the intriguing and elusive role of Vasa proteins within germ granules in determining whether a cell is destined to become a germ cell with totipotent capabilities or a specific type of cell, like those that comprise muscle, nerves or skin.

Because of the role of Vasa proteins in preserving totipotency, an increased understanding of how such proteins work could lead to unprecedented approaches to de-differentiating cell types to promote regeneration; or alternatively, to new methods to turn off totipotency when it is no longer desirable, as in the case of cancer.

The increase in chronic and degenerative diseases caused by the aging of the population is driving demand for new therapies, said MDI Biological Laboratory President Hermann Haller, M.D. Dustins research on germ granules offers another route to repairing damaged tissues and organs in cases where therapeutic options are limited or non-existent, as well as an increased understanding of cancer.

Because of the complexity of the cellular chemistry, research on Vasa and other proteins found in germ granules is often overlooked, but that is rapidly changing especially among pharmaceutical companies as more scientists realize the impact and potential of such research, not only for regenerative medicine but also for an understanding of tumorigenesis, or cancer development, Updike said.

Recent research has found that some cancers are accompanied by the mis-expression of germ granule proteins, which are normally found only in germ cells. The mis-expression of these germ-granule proteins seems to promote the immortal properties of germ cells, and consequently tumorigenesis, with some germ-granule proteins now serving as prognosis markers for different types of cancer, Updike said.

Updike is a former postdoctoral researcher in the laboratory of Susan Strome, Ph.D., at University of California, Santa Cruz. Strome, who was inducted into the National Academy of Sciences last year, first discovered P granules more than 30 years ago. She credits Updike, who has published several seminal papers on the subject, with great imagination, determination and excellent technical skill in the pursuit of his goal of elucidating the function and biochemistry of these tiny organelles.

The lead author of the new study from the Updike laboratory, Elisabeth A. Marnik, Ph.D., will be launching her own laboratory at Husson University in Bangor, Maine, this fall. Other contributors include J. Heath Fuqua, Catherine S. Sharp, Jesse D. Rochester, Emily L. Xu and Sarah E. Holbrook. Their research was conducted at the Kathryn W. Davis Center for Regenerative Biology and Medicine at the MDI Biological Laboratory.

Updikes research is supported by a grant (R01 GM-113933) from the National Institute of General Medical Sciences (NIGMS), an institute of the National Institutes of Health (NIH). The equipment and cores used for part of the study were supported by NIGMS-NIH Centers of Biomedical Research Excellence and IDeA Networks of Biomedical Research Excellence grants P20 GM-104318 and P20 GM-203423, respectively.

We aim to improve human health and healthspan by uncovering basic mechanisms of tissue repair, aging and regeneration, translating our discoveries for the benefit of society and developing the next generation of scientific leaders. For more information, please visitmdibl.org.

Go here to read the rest:
Research at MDI Biological Laboratory explores novel pathways of regeneration and tumorigenesis - Bangor Daily News

Cell Biology

Life Science Tools & Reagents Market Brief Analysis and Application, Growth by 2026 – News Distinct

QY Research as of late produced a research report titled, Life Science Tools & Reagents . The research report speak about the potential development openings that exist in the worldwide market. The report is broken down on the basis of research procedures procured from historical and forecast information. The global Life Science Tools & Reagents market is relied upon to develop generously and flourish as far as volume and incentive during the gauge time frame. The report will give a knowledge about the development openings and controls that will build the market. Pursuers can increase important perception about the eventual fate of the market.

Key companies that are operating in the global Life Science Tools & Reagents market are: , Abbott Laboratories, Abcam, BD Biosciences, Beckman Coulter Inc., Benitec, Bio-Rad Laboratories, Cell Sciences, Cell Signaling Technology, Cepheid Inc., Charles River Laboratories International Inc., Echelon Biosciences Inc., Emd Millipore, Enzo Biochem, High Throughput Genomics Inc., Illumina Inc., Lifesensors Inc., Lonza Group AG, Luminex Corp., Stemgent, Sysmex-Partec Gmbh, Thermo Fisher Scientific Inc., Trilink Biotechnologies, Tocris Bioscience (Bio-Techne), Vitro Diagnostics Inc., Waters Corp., Xenotech Llc

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1540823/global-life-science-tools-amp-reagents-market

Segmental Analysis

The report incorporates significant sections, for example, type and end user and a variety of segments that decide the prospects of the market. Each type provide data with respect to the business esteem during the conjecture time frame. The application area likewise gives information by volume and consumption during the estimate time frame. The comprehension of this segment direct the readers in perceiving the significance of variables that shape the market development.

Global Life Science Tools & Reagents Market Segment By Type:

, Tools, Reagents

Global Life Science Tools & Reagents Market Segment By Application:

, Proteomics, Cell biology research, Epigenetics, Metabolomics, Bioinformatics, Others

Competitive Landscape

The report incorporates various key players and producers working in the local and worldwide market. This segment shows the procedures received by players in the market to remain ahead in the challenge. New patterns and its reception by players assist readers with understanding the elements of the business and how it very well may be utilized to their own benefit. The readers can likewise recognize the strides of players to comprehend the global market better.

Key companies operating in the global Life Science Tools & Reagents market include , Abbott Laboratories, Abcam, BD Biosciences, Beckman Coulter Inc., Benitec, Bio-Rad Laboratories, Cell Sciences, Cell Signaling Technology, Cepheid Inc., Charles River Laboratories International Inc., Echelon Biosciences Inc., Emd Millipore, Enzo Biochem, High Throughput Genomics Inc., Illumina Inc., Lifesensors Inc., Lonza Group AG, Luminex Corp., Stemgent, Sysmex-Partec Gmbh, Thermo Fisher Scientific Inc., Trilink Biotechnologies, Tocris Bioscience (Bio-Techne), Vitro Diagnostics Inc., Waters Corp., Xenotech Llc

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1540823/global-life-science-tools-amp-reagents-market

TOC

Table of Contents 1 Life Science Tools & Reagents Market Overview1.1 Life Science Tools & Reagents Product Overview1.2 Life Science Tools & Reagents Market Segment by Type1.2.1 Tools1.2.2 Reagents1.3 Global Life Science Tools & Reagents Market Size by Type (2015-2026)1.3.1 Global Life Science Tools & Reagents Market Size Overview by Type (2015-2026)1.3.2 Global Life Science Tools & Reagents Historic Market Size Review by Type (2015-2020)

1.3.2.1 Global Life Science Tools & Reagents Sales Market Share Breakdown by Type (2015-2026)

1.3.2.2 Global Life Science Tools & Reagents Revenue Market Share Breakdown by Type (2015-2026)

1.3.2.3 Global Life Science Tools & Reagents Average Selling Price (ASP) by Type (2015-2026)1.3.3 Global Life Science Tools & Reagents Market Size Forecast by Type (2021-2026)

1.3.3.1 Global Life Science Tools & Reagents Sales Market Share Breakdown by Application (2021-2026)

1.3.3.2 Global Life Science Tools & Reagents Revenue Market Share Breakdown by Application (2021-2026)

1.3.3.3 Global Life Science Tools & Reagents Average Selling Price (ASP) by Application (2021-2026)1.4 Key Regions Market Size Segment by Type (2015-2020)1.4.1 North America Life Science Tools & Reagents Sales Breakdown by Type (2015-2026)1.4.2 Europe Life Science Tools & Reagents Sales Breakdown by Type (2015-2026)1.4.3 Asia-Pacific Life Science Tools & Reagents Sales Breakdown by Type (2015-2026)1.4.4 Latin America Life Science Tools & Reagents Sales Breakdown by Type (2015-2026)1.4.5 Middle East and Africa Life Science Tools & Reagents Sales Breakdown by Type (2015-2026) 2 Global Life Science Tools & Reagents Market Competition by Company2.1 Global Top Players by Life Science Tools & Reagents Sales (2015-2020)2.2 Global Top Players by Life Science Tools & Reagents Revenue (2015-2020)2.3 Global Top Players Life Science Tools & Reagents Average Selling Price (ASP) (2015-2020)2.4 Global Top Manufacturers Life Science Tools & Reagents Manufacturing Base Distribution, Sales Area, Product Type2.5 Life Science Tools & Reagents Market Competitive Situation and Trends2.5.1 Life Science Tools & Reagents Market Concentration Rate (2015-2020)2.5.2 Global 5 and 10 Largest Manufacturers by Life Science Tools & Reagents Sales and Revenue in 20192.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Life Science Tools & Reagents as of 2019)2.7 Date of Key Manufacturers Enter into Life Science Tools & Reagents Market2.8 Key Manufacturers Life Science Tools & Reagents Product Offered2.9 Mergers & Acquisitions, Expansion 3 Global Life Science Tools & Reagents Status and Outlook by Region (2015-2026)3.1 Global Life Science Tools & Reagents Market Size and CAGR by Region: 2015 VS 2020 VS 20263.2 Global Life Science Tools & Reagents Market Size Market Share by Region (2015-2020)3.2.1 Global Life Science Tools & Reagents Sales Market Share by Region (2015-2020)3.2.2 Global Life Science Tools & Reagents Revenue Market Share by Region (2015-2020)3.2.3 Global Life Science Tools & Reagents Sales, Revenue, Price and Gross Margin (2015-2020)3.3 Global Life Science Tools & Reagents Market Size Market Share by Region (2021-2026)3.3.1 Global Life Science Tools & Reagents Sales Market Share by Region (2021-2026)3.3.2 Global Life Science Tools & Reagents Revenue Market Share by Region (2021-2026)3.3.3 Global Life Science Tools & Reagents Sales, Revenue, Price and Gross Margin (2021-2026)3.4 North America Life Science Tools & Reagents Market Size YoY Growth (2015-2026)3.4.1 North America Life Science Tools & Reagents Revenue YoY Growth (2015-2026)3.4.2 North America Life Science Tools & Reagents Sales YoY Growth (2015-2026)3.5 Asia-Pacific Life Science Tools & Reagents Market Size YoY Growth (2015-2026)3.5.1 Asia-Pacific Life Science Tools & Reagents Revenue YoY Growth (2015-2026)3.5.2 Asia-Pacific Life Science Tools & Reagents Sales YoY Growth (2015-2026)3.6 Europe Life Science Tools & Reagents Market Size YoY Growth (2015-2026)3.6.1 Europe Life Science Tools & Reagents Revenue YoY Growth (2015-2026)3.6.2 Europe Life Science Tools & Reagents Sales YoY Growth (2015-2026)3.7 Latin America Life Science Tools & Reagents Market Size YoY Growth (2015-2026)3.7.1 Latin America Life Science Tools & Reagents Revenue YoY Growth (2015-2026)3.7.2 Latin America Life Science Tools & Reagents Sales YoY Growth (2015-2026)3.8 Middle East and Africa Life Science Tools & Reagents Market Size YoY Growth (2015-2026)3.8.1 Middle East and Africa Life Science Tools & Reagents Revenue YoY Growth (2015-2026)3.8.2 Middle East and Africa Life Science Tools & Reagents Sales YoY Growth (2015-2026) 4 Global Life Science Tools & Reagents by Application4.1 Life Science Tools & Reagents Segment by Application4.1.1 Proteomics4.1.2 Cell biology research4.1.3 Epigenetics4.1.4 Metabolomics4.1.5 Bioinformatics4.1.6 Others4.2 Global Life Science Tools & Reagents Sales by Application: 2015 VS 2020 VS 20264.3 Global Life Science Tools & Reagents Historic Sales by Application (2015-2020)4.4 Global Life Science Tools & Reagents Forecasted Sales by Application (2021-2026)4.5 Key Regions Life Science Tools & Reagents Market Size by Application4.5.1 North America Life Science Tools & Reagents by Application4.5.2 Europe Life Science Tools & Reagents by Application4.5.3 Asia-Pacific Life Science Tools & Reagents by Application4.5.4 Latin America Life Science Tools & Reagents by Application4.5.5 Middle East and Africa Life Science Tools & Reagents by Application 5 North America Life Science Tools & Reagents Market Size by Country (2015-2026)5.1 North America Market Size Market Share by Country (2015-2020)5.1.1 North America Life Science Tools & Reagents Sales Market Share by Country (2015-2020)5.1.2 North America Life Science Tools & Reagents Revenue Market Share by Country (2015-2020)5.2 North America Market Size Market Share by Country (2021-2026)5.2.1 North America Life Science Tools & Reagents Sales Market Share by Country (2021-2026)5.2.2 North America Life Science Tools & Reagents Revenue Market Share by Country (2021-2026)5.3 North America Market Size YoY Growth by Country5.3.1 U.S. Life Science Tools & Reagents Market Size YoY Growth (2015-2026)5.3.2 Canada Life Science Tools & Reagents Market Size YoY Growth (2015-2026) 6 Europe Life Science Tools & Reagents Market Size by Country (2015-2026)6.1 Europe Market Size Market Share by Country (2015-2020)6.1.1 Europe Life Science Tools & Reagents Sales Market Share by Country (2015-2020)6.1.2 Europe Life Science Tools & Reagents Revenue Market Share by Country (2015-2020)6.2 Europe Market Size Market Share by Country (2021-2026)6.2.1 Europe Life Science Tools & Reagents Sales Market Share by Country (2021-2026)6.2.2 Europe Life Science Tools & Reagents Revenue Market Share by Country (2021-2026)6.3 Europe Market Size YoY Growth by Country6.3.1 Germany Life Science Tools & Reagents Market Size YoY Growth (2015-2026)6.3.2 France Life Science Tools & Reagents Market Size YoY Growth (2015-2026)6.3.3 U.K. Life Science Tools & Reagents Market Size YoY Growth (2015-2026)6.3.4 Italy Life Science Tools & Reagents Market Size YoY Growth (2015-2026)6.3.5 Russia Life Science Tools & Reagents Market Size YoY Growth (2015-2026) 7 Asia-Pacific Life Science Tools & Reagents Market Size by Country (2015-2026)7.1 Asia-Pacific Market Size Market Share by Country (2015-2020)7.1.1 Asia-Pacific Life Science Tools & Reagents Sales Market Share by Country (2015-2020)7.1.2 Asia-Pacific Life Science Tools & Reagents Revenue Market Share by Country (2015-2020)7.2 Asia-Pacific Market Size Market Share by Country (2021-2026)7.2.1 Asia-Pacific Life Science Tools & Reagents Sales Market Share by Country (2021-2026)7.2.2 Asia-Pacific Life Science Tools & Reagents Revenue Market Share by Country (2021-2026)7.3 Asia-Pacific Market Size YoY Growth by Country7.3.1 China Life Science Tools & Reagents Market Size YoY Growth (2015-2026)7.3.2 Japan Life Science Tools & Reagents Market Size YoY Growth (2015-2026)7.3.3 South Korea Life Science Tools & Reagents Market Size YoY Growth (2015-2026)7.3.4 India Life Science Tools & Reagents Market Size YoY Growth (2015-2026)7.3.5 Australia Life Science Tools & Reagents Market Size YoY Growth (2015-2026)7.3.6 Taiwan Life Science Tools & Reagents Market Size YoY Growth (2015-2026)7.3.7 Indonesia Life Science Tools & Reagents Market Size YoY Growth (2015-2026)7.3.8 Thailand Life Science Tools & Reagents Market Size YoY Growth (2015-2026)7.3.9 Malaysia Life Science Tools & Reagents Market Size YoY Growth (2015-2026)7.3.10 Philippines Life Science Tools & Reagents Market Size YoY Growth (2015-2026)7.3.11 Vietnam Life Science Tools & Reagents Market Size YoY Growth (2015-2026) 8 Latin America Life Science Tools & Reagents Market Size by Country (2015-2026)8.1 Latin America Market Size Market Share by Country (2015-2020)8.1.1 Latin America Life Science Tools & Reagents Sales Market Share by Country (2015-2020)8.1.2 Latin America Life Science Tools & Reagents Revenue Market Share by Country (2015-2020)8.2 Latin America Market Size Market Share by Country (2021-2026)8.2.1 Latin America Life Science Tools & Reagents Sales Market Share by Country (2021-2026)8.2.2 Latin America Life Science Tools & Reagents Revenue Market Share by Country (2021-2026)8.3 Latin America Market Size YoY Growth by Country8.3.1 Mexico Life Science Tools & Reagents Market Size YoY Growth (2015-2026)8.3.2 Brazil Life Science Tools & Reagents Market Size YoY Growth (2015-2026)8.3.3 Argentina Life Science Tools & Reagents Market Size YoY Growth (2015-2026) 9 Middle East and Africa Life Science Tools & Reagents Market Size by Country (2015-2026)9.1 Middle East and Africa Market Size Market Share by Country (2015-2020)9.1.1 Middle East and Africa Life Science Tools & Reagents Sales Market Share by Country (2015-2020)9.1.2 Middle East and Africa Life Science Tools & Reagents Revenue Market Share by Country (2015-2020)9.2 Middle East and Africa Market Size Market Share by Country (2021-2026)9.2.1 Middle East and Africa Life Science Tools & Reagents Sales Market Share by Country (2021-2026)9.2.2 Middle East and Africa Life Science Tools & Reagents Revenue Market Share by Country (2021-2026)9.3 Middle East and Africa Market Size YoY Growth by Country9.3.1 Turkey Life Science Tools & Reagents Market Size YoY Growth (2015-2026)9.3.2 Saudi Arabia Life Science Tools & Reagents Market Size YoY Growth (2015-2026)9.3.3 U.A.E Life Science Tools & Reagents Market Size YoY Growth (2015-2026) 10 Company Profiles and Key Figures in Life Science Tools & Reagents Business10.1 Abbott Laboratories10.1.1 Abbott Laboratories Corporation Information10.1.2 Abbott Laboratories Description, Business Overview and Total Revenue10.1.3 Abbott Laboratories Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.1.4 Abbott Laboratories Life Science Tools & Reagents Products Offered10.1.5 Abbott Laboratories Recent Development10.2 Abcam10.2.1 Abcam Corporation Information10.2.2 Abcam Description, Business Overview and Total Revenue10.2.3 Abcam Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.2.5 Abcam Recent Development10.3 BD Biosciences10.3.1 BD Biosciences Corporation Information10.3.2 BD Biosciences Description, Business Overview and Total Revenue10.3.3 BD Biosciences Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.3.4 BD Biosciences Life Science Tools & Reagents Products Offered10.3.5 BD Biosciences Recent Development10.4 Beckman Coulter Inc.10.4.1 Beckman Coulter Inc. Corporation Information10.4.2 Beckman Coulter Inc. Description, Business Overview and Total Revenue10.4.3 Beckman Coulter Inc. Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.4.4 Beckman Coulter Inc. Life Science Tools & Reagents Products Offered10.4.5 Beckman Coulter Inc. Recent Development10.5 Benitec10.5.1 Benitec Corporation Information10.5.2 Benitec Description, Business Overview and Total Revenue10.5.3 Benitec Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.5.4 Benitec Life Science Tools & Reagents Products Offered10.5.5 Benitec Recent Development10.6 Bio-Rad Laboratories10.6.1 Bio-Rad Laboratories Corporation Information10.6.2 Bio-Rad Laboratories Description, Business Overview and Total Revenue10.6.3 Bio-Rad Laboratories Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.6.4 Bio-Rad Laboratories Life Science Tools & Reagents Products Offered10.6.5 Bio-Rad Laboratories Recent Development10.7 Cell Sciences10.7.1 Cell Sciences Corporation Information10.7.2 Cell Sciences Description, Business Overview and Total Revenue10.7.3 Cell Sciences Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.7.4 Cell Sciences Life Science Tools & Reagents Products Offered10.7.5 Cell Sciences Recent Development10.8 Cell Signaling Technology10.8.1 Cell Signaling Technology Corporation Information10.8.2 Cell Signaling Technology Description, Business Overview and Total Revenue10.8.3 Cell Signaling Technology Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.8.4 Cell Signaling Technology Life Science Tools & Reagents Products Offered10.8.5 Cell Signaling Technology Recent Development10.9 Cepheid Inc.10.9.1 Cepheid Inc. Corporation Information10.9.2 Cepheid Inc. Description, Business Overview and Total Revenue10.9.3 Cepheid Inc. Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.9.4 Cepheid Inc. Life Science Tools & Reagents Products Offered10.9.5 Cepheid Inc. Recent Development10.10 Charles River Laboratories International Inc.10.10.1 Company Basic Information, Manufacturing Base and Competitors10.10.2 Life Science Tools & Reagents Product Category, Application and Specification10.10.3 Charles River Laboratories International Inc. Life Science Tools & Reagents Sales, Revenue, Price and Gross Margin (2015-2020)10.10.4 Main Business Overview10.10.5 Charles River Laboratories International Inc. Recent Development10.11 Echelon Biosciences Inc.10.11.1 Echelon Biosciences Inc. Corporation Information10.11.2 Echelon Biosciences Inc. Description, Business Overview and Total Revenue10.11.3 Echelon Biosciences Inc. Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.11.4 Echelon Biosciences Inc. Life Science Tools & Reagents Products Offered10.11.5 Echelon Biosciences Inc. Recent Development10.12 Emd Millipore10.12.1 Emd Millipore Corporation Information10.12.2 Emd Millipore Description, Business Overview and Total Revenue10.12.3 Emd Millipore Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.12.4 Emd Millipore Life Science Tools & Reagents Products Offered10.12.5 Emd Millipore Recent Development10.13 Enzo Biochem10.13.1 Enzo Biochem Corporation Information10.13.2 Enzo Biochem Description, Business Overview and Total Revenue10.13.3 Enzo Biochem Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.13.4 Enzo Biochem Life Science Tools & Reagents Products Offered10.13.5 Enzo Biochem Recent Development10.14 High Throughput Genomics Inc.10.14.1 High Throughput Genomics Inc. Corporation Information10.14.2 High Throughput Genomics Inc. Description, Business Overview and Total Revenue10.14.3 High Throughput Genomics Inc. Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.14.4 High Throughput Genomics Inc. Life Science Tools & Reagents Products Offered10.14.5 High Throughput Genomics Inc. Recent Development10.15 Illumina Inc.10.15.1 Illumina Inc. Corporation Information10.15.2 Illumina Inc. Description, Business Overview and Total Revenue10.15.3 Illumina Inc. Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.15.4 Illumina Inc. Life Science Tools & Reagents Products Offered10.15.5 Illumina Inc. Recent Development10.16 Lifesensors Inc.10.16.1 Lifesensors Inc. Corporation Information10.16.2 Lifesensors Inc. Description, Business Overview and Total Revenue10.16.3 Lifesensors Inc. Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.16.4 Lifesensors Inc. Life Science Tools & Reagents Products Offered10.16.5 Lifesensors Inc. Recent Development10.17 Lonza Group AG10.17.1 Lonza Group AG Corporation Information10.17.2 Lonza Group AG Description, Business Overview and Total Revenue10.17.3 Lonza Group AG Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.17.4 Lonza Group AG Life Science Tools & Reagents Products Offered10.17.5 Lonza Group AG Recent Development10.18 Luminex Corp.10.18.1 Luminex Corp. Corporation Information10.18.2 Luminex Corp. Description, Business Overview and Total Revenue10.18.3 Luminex Corp. Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.18.4 Luminex Corp. Life Science Tools & Reagents Products Offered10.18.5 Luminex Corp. Recent Development10.19 Stemgent10.19.1 Stemgent Corporation Information10.19.2 Stemgent Description, Business Overview and Total Revenue10.19.3 Stemgent Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.19.4 Stemgent Life Science Tools & Reagents Products Offered10.19.5 Stemgent Recent Development10.20 Sysmex-Partec Gmbh10.20.1 Sysmex-Partec Gmbh Corporation Information10.20.2 Sysmex-Partec Gmbh Description, Business Overview and Total Revenue10.20.3 Sysmex-Partec Gmbh Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.20.4 Sysmex-Partec Gmbh Life Science Tools & Reagents Products Offered10.20.5 Sysmex-Partec Gmbh Recent Development10.21 Thermo Fisher Scientific Inc.10.21.1 Thermo Fisher Scientific Inc. Corporation Information10.21.2 Thermo Fisher Scientific Inc. Description, Business Overview and Total Revenue10.21.3 Thermo Fisher Scientific Inc. Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.21.4 Thermo Fisher Scientific Inc. Life Science Tools & Reagents Products Offered10.21.5 Thermo Fisher Scientific Inc. Recent Development10.22 Trilink Biotechnologies10.22.1 Trilink Biotechnologies Corporation Information10.22.2 Trilink Biotechnologies Description, Business Overview and Total Revenue10.22.3 Trilink Biotechnologies Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.22.4 Trilink Biotechnologies Life Science Tools & Reagents Products Offered10.22.5 Trilink Biotechnologies Recent Development10.23 Tocris Bioscience (Bio-Techne)10.23.1 Tocris Bioscience (Bio-Techne) Corporation Information10.23.2 Tocris Bioscience (Bio-Techne) Description, Business Overview and Total Revenue10.23.3 Tocris Bioscience (Bio-Techne) Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.23.4 Tocris Bioscience (Bio-Techne) Life Science Tools & Reagents Products Offered10.23.5 Tocris Bioscience (Bio-Techne) Recent Development10.24 Vitro Diagnostics Inc.10.24.1 Vitro Diagnostics Inc. Corporation Information10.24.2 Vitro Diagnostics Inc. Description, Business Overview and Total Revenue10.24.3 Vitro Diagnostics Inc. Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.24.4 Vitro Diagnostics Inc. Life Science Tools & Reagents Products Offered10.24.5 Vitro Diagnostics Inc. Recent Development10.25 Waters Corp.10.25.1 Waters Corp. Corporation Information10.25.2 Waters Corp. Description, Business Overview and Total Revenue10.25.3 Waters Corp. Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.25.4 Waters Corp. Life Science Tools & Reagents Products Offered10.25.5 Waters Corp. Recent Development10.26 Xenotech Llc10.26.1 Xenotech Llc Corporation Information10.26.2 Xenotech Llc Description, Business Overview and Total Revenue10.26.3 Xenotech Llc Life Science Tools & Reagents Sales, Revenue and Gross Margin (2015-2020)10.26.4 Xenotech Llc Life Science Tools & Reagents Products Offered10.26.5 Xenotech Llc Recent Development 11 Life Science Tools & Reagents Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis11.1 Life Science Tools & Reagents Key Raw Materials11.1.1 Key Raw Materials11.1.2 Key Raw Materials Price11.1.3 Raw Materials Key Suppliers11.2 Manufacturing Cost Structure11.2.1 Raw Materials11.2.2 Labor Cost11.2.3 Manufacturing Expenses11.3 Life Science Tools & Reagents Industrial Chain Analysis11.4 Market Opportunities, Challenges, Risks and Influences Factors Analysis11.4.1 Market Opportunities and Drivers11.4.2 Market Challenges11.4.3 Market Risks11.4.4 Porters Five Forces Analysis 12 Market Strategy Analysis, Distributors12.1 Sales Channel12.2 Distributors12.3 Downstream Customers 13 Research Findings and Conclusion 14 Appendix14.1 Methodology/Research Approach14.1.1 Research Programs/Design14.1.2 Market Size Estimation14.1.3 Market Breakdown and Data Triangulation14.2 Data Source14.2.1 Secondary Sources14.2.2 Primary Sources14.3 Author Details14.4 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Follow this link:
Life Science Tools & Reagents Market Brief Analysis and Application, Growth by 2026 - News Distinct

Cell Biology

Benchling, BERG, Thermo Fisher Scientific, And More: News From May 2020 – Bio-IT World

May 27, 2020 |May featured exciting new, products, and partnerships from around the bio-IT community from innovating companies, organizations, and universities, including Benchling, BERG, Thermo Fisher Scientific, and more.

Benchlingannounced the launch ofBenchling Insights, a new solution that gives life sciences companies the ability to query, visualize and collaborate around high quality, structured data that resides on the platform. While the biotech industry continues to grow, companies are faced with increased competition, patent expirations and increased scrutiny over pricing and efficacy. Biotech companies are under immense pressure to deliver new products into clinical evaluation faster than ever, which requires disciplined execution, a high degree of collaboration and unfettered access to data across the R&D lifecycle, saidSaji Wickramasekara, CEO and Co-Founder of Benchling, in a press release. We launched Benchling Insights so that our customers can make intelligent decisions with a complete view of their experimental and operational data. Analyses and dashboards can be rapidly created and shared across programs, teams, and leadership so companies can reach breakthroughs faster. Benchling Insights extends the Benchling Life Sciences R&D Cloudwith an integrated solution for data querying, visualization, and collaboration. Scientists can tailor advanced queries to visualize scientific and operational metrics, and use these to quickly answer key questions about their programs. For example, they can assess which cell lines generate the best assay performance, or which process variants lead to optimal outputs. R&D leaders can use centralized data to track overall pipeline performance and remove operational bottlenecks, while IT leaders can track product utilization and compliance. Press release

BERGannounced a new collaboration with Boehringer Ingelheimaround understanding the multifaceted nature of the spectrum of inflammatory diseases and seeks to unravel the associated biological drivers. The pilot program with Boehringer Ingelheim will work to reveal novel insights into the complexities of various inflammatory diseases. The potential outcomes of this partnership could lead to a broader understanding of the etiology of potential candidate biomarkers. BERG has previously collaborated with multiple pharmaceutical companies and applied its Interrogative Biologyplatform to diverse datasets to address major clinical unmet needs. Were excited to partner with Boehringer Ingelheim, which will combine Boehringer Ingelheim's translational medicine and biomarker expertise with BERGs next generation AI-driven, patient-biology capability, Niven R. Narain, BERG Co-founder, President and Chief Executive Officer, said in a press release. Our intent is for BERGs Interrogative Biology platform to enable the discoveryofbiomarkersthat willrevolutionize how to diagnose and treat patients with inflammatory diseases. Press release

Thermo Fisher Scientificreleased the Thermo Scientific Helios 5 Laser PFIBsystem, an advanced focused ion beam scanning electron microscope (FIB-SEM) with a fully integrated femtosecond laser that quickly characterizes millimeter-scale volumes of material in 3D with nanometer resolution. The Helios 5 Laser PFIB combines the best-in-class Thermo Scientific Elstar SEM Columnfor ultra-high-resolution imaging and advanced analytical capabilities with a plasma FIB column for top performance at all operating conditions, and a femtosecond laser that enables in-situ ablation at material removal rates not previously obtained by a commercially available product. The Helios 5 Laser PFIB is part of the fifth generation of the industry-leading Helios family. The Helios 5 Laser PFIB dramatically accelerates the pace of research for both academic and industrial users, allowing them to characterize materials in a matter of minutes versus the days it took before,Rosy Lee, vice president of materials science at Thermo Fisher, said in a press release. Not only can researchers quickly and accurately image statistically relevant, site-specific, millimeter-size cross-sections at nanoscale resolution, they can also set up large-volume 3D analyses to be automatically completed overnight, freeing up the microscope for other uses. The Helios 5 Laser PFIB allows researchers to obtain accurate large-volume 3D and sub-surface data up to 15,000 times faster than a typical Gallium ion source focused ion beam (Ga-FIB). For many materials, a large cross-section of hundreds of microns can be milled by the Helios 5 Laser PFIB in less than 5 minutes. Serial-section tomography is now possible with this combination of Laser and Plasma FIB, and when combined with EDS and EBSD detectors, can be extended to 3D elemental and grain orientation analysis at the millimeter scale. Press release

Following the recent launch of NVIDIAs new DGX A100system, NetApp ONTAP AIannounced it will be among the first converged AI stacks to incorporate the DGX A100 and NVIDIA Mellanox networking. NetApp and NVIDIA have been collaborating for several years to deliver AI solutions that help enterprises accelerate AI adoption. Both companies are working on eliminating AI bottlenecks and advancing the realm of possibilities, Kim Stevenson, Sr. Vice President and General Manager, Foundational Data Services Business Unit, NetApp, said in an official statement. NetApps full stack AI/ML/DL platforms delivered at the edge, core and cloud with ONTAP AI complements NVIDIAs rapidly expanding ecosystem of AI hardware, software, and development toolkits. Blog post

Advanced Biological Laboratories (ABL)announced the CE-IVDmarking of its DeepChek-HIVAssays is now available for in-vitro diagnostics. Intended to be used on HIV-1 Group M viruses from patients diagnosed with HIV infection, the assays deliver standardized, open and flexible solution suited to clinical settings performing sequencing through Capillary Electrophoresis and Next Generation Sequencing (NGS) systems. The DeepChek-HIV CE IVD Assays are covering respectively the Protease / Reverse Transcriptase and the Integrase regions of the virus and are intended to be used from input RNA extracted from plasma, serum or whole blood samples. Both assays are highly sensitive and have been validated to process clinical samples as low as 1,000 copies/mL with outstanding performances (100% agreement of analytical reproducibility and repeatability, 100% clinical reproducibility, 99% clinical sensitivity) in all three regions. Open and flexible, the DeepChek-HIV CE IVD Assays is a unique and versatile system that can be used under a large variety of laboratory throughput configurations. Obtaining CE IVD marking for our DeepChek-HIV assays will allow virology labs to access a unique and innovative technology, for HIV genotyping diagnostics. ABL will keep standardizing its entire portfolio of applications in virology and microbiology following European and International guidelines to improve the management of patients suffering from chronic diseases on a worldwide basis, Chalom Sayada, CEO of ABL, said in an official statement. Press release

Cardinal Healthand Vinetiannounced a collaboration to support cell and gene therapy manufacturers with a fully integrated solution that aligns logistics and commercialization services with digital Chain of Identityand Chain of Custodythroughout the treatment journey. Cardinal Healthsupports the cell and gene therapy market with a robust suite of services that includes end-to-end logistics, regulatory strategy, order-to-cash management and patient access and support services. Vineti offers a digital platform of record to integrate logistics, manufacturing and clinical data for cell and gene therapies. The Vineti platform delivers digital Chain of Identity and Chain of Custody, providing essential patient safety and regulatory compliance across the value chain.Together, Cardinal Health and Vineti will develop best-in-class solutions to support the distribution of transformative, personalized therapies for cancer and other serious diseases.Specifically, Cardinal Health and Vineti will focus on integrated solutions that enable cell and gene therapy manufacturers to accelerate the commercialization of their products, while delivering a more simple, seamless and secure experience to hospitals and patients, from initial patient enrollment through delivery of the final dose of therapy and beyond. Press release

Immunailaunched out of stealth to map the entire immune system for better detection, diagnosis, and treatment of disease. Leveraging single-cell technologies and machine learning algorithms, Immunai has mapped out millions of immune cells and their functions, building the largest proprietary data set in the world for clinical immunological data. The company is also announcing $20M in seed funding, which will be used to further the development of its technology and business functions while expanding its team of scientists, engineers, and machine learning experts. Cell therapies and cancer immunotherapies have revolutionized medicine in the last few years and are expected to continue for the near future. However, due to the incredible complexity of the immune systemits trillions of cells partitioned into hundreds of cell types and states and how they interplay with other cells and proteinsit is prohibitively hard to predict how drugs will affect immune cells. For cell therapies with high manufacturing costs, a slight variation in cell therapy products can have a significant influence on a patients response to the therapy.Immunai has developed a vertically-integrated platform for multi-omic single-cell profiling that offers a broader view of the immune system in states of health, disease, and treatment to examine the bodys response to stimulus. With Immunais platform, pharmaceutical companies can identify more subtle nuances in cell abundances and cell function and mechanisms of action and biomarkers for toxicity response to accurately measure the efficacy of immunotherapies. For cell therapies, in particular, Immunai partners with cell therapy companies to understand cellular products sub-populations in unprecedented detail before and after infusion.Press release

Read more here:
Benchling, BERG, Thermo Fisher Scientific, And More: News From May 2020 - Bio-IT World

Cell Biology

Eye Injury Sets Immune Cells On Surveillance To Protect The Lens – Newswise

Newswise PHILADELPHIA The lens of the eye is an unusual organ. Unlike most of the bodys organs, blood vessels dont reach the lens. If they did, theyd obscure our vision and we wouldnt be able to see. The lack of vasculature led scientists to believe immune cells, which travel via the bloodstream, couldnt get to this part of the body either. But a few years ago, Jefferson researchers challenged this long held assumption by demonstrating that immune cells populate the lens in response to degeneration. Now the Jefferson team finds the eye also launches an immune response in the lens after injury. The discovery adds to a growing body of evidence that is working to overturn the accepted dogma of the field.

Why would we evolve a tissue that is so central to our being able to see without ways to ensure its protection, its ability to repair itself? says, Sue Menko, PhD, Professor in the Department of Pathology, Anatomy and Cell Biology atThomas Jefferson University,who led the research. "Immune cells are central to that protection and repair.

The lens of the eye works like a camera lens. Its main purpose is to focus images coming in through the cornea the transparent front layer of the eye onto the retina at the back of the eye. The images are detected by the retina and then translated in the brain as what we see. That lens must be crystal clear. As a result, scientists have always described the lens as a tissue without vasculature and therefore no source of immune cells either.

At some point, you think about it and you wonder how thats possible, Dr. Menko says. It doesnt really make a lot of sense.

The puzzle led Dr. Menko and her team to investigate whether immune cells are present in the eye. In a previous study, they discovered that when the lens is in a diseased state, immune cells are not only recruited there, but they also show up in the cornea, retina, and vitreous body all parts of the eye that dont normally have immune cells. Dr. Menkos work suggested that the immune cells come from the ciliary body, a sort of muscle that helps squeeze and pull the lens, changing its shape, and helping it focus.

The ciliary body is also a place that is vascular rich so it seemed like the most obvious place to look, Dr. Menko says.

Now, in the latest work, Dr. Menko and colleagues show that after injury to the cornea, immune cells travel from the ciliary body to the lens along fibers known as ciliary zonules. The researchers used fluorescent markers and high-powered microscopes to observe structures of mouse eyes one day after receiving a scratch on the cornea. The high-tech imaging analysis Dr. Menkos team used revealed that following injury to the cornea, the immune system launches a response to protect the lens. Immune cells are recruited to the lens via the ciliary zonules, and crawl along the surface of the lens to surveille and protect from adverse impacts of the corneal wound.

This is really the first demonstration that surveillance by immune cells of the lens in response to injury somewhere else in the eye, Dr. Menko says.

The researchers also found that some immune cells were able to cross the lens capsule, a membranous structure that helps to keep the lens under tension. The results could point to a role for immune cells in cataract formation.

Together, the findings indicate that in response to damage or disease, the eye utilizes alternative mechanisms rather than direct contact with the bloodstream like non-transparent tissues do to ensure that immune cells get to sites to provide healing and protection.

Were excited to go from thinking this doesnt make sense to proving that the body is amazing and can adapt to anything. You just have to go in and look for it, Dr. Menko says.

We should be willing to challenge dogma because that's where discovery is, she adds. It can enlighten what we know if we always keep our mind open to what doesnt make sense and what maybe should be challenged to understand things better.

Dr. Menko and colleagues published the results on May 25th in The FASEB Journal.

Article reference: JodiRae DeDreu, Caitlin J. Bowen, Caitlin M. Logan, Sonali Pal-Ghosh, Paola Parlanti, Mary Ann Stepp, and A. Sue Menko, An immune response to the avascular lens following wounding of the cornea involves ciliary zonule fibrils, The FASEB Journal, DOI: 10.1096/fj.202000289R, 2020.

Visit link:
Eye Injury Sets Immune Cells On Surveillance To Protect The Lens - Newswise

Cell Biology

New Liver Cancer Research Targets Non-Cancer Cells to Blunt Tumor Growth – Newswise

Newswise PHILADELPHIA Senotherapy, a treatment that uses small molecule drugs to target senescent cells, or those cells that no longer undergo cell division, blunts liver tumor progression in animal models according to new research from a team led by Celeste Simon, PhD, a professor of Cell and Developmental Biology in the Perelman School of Medicine at the University of Pennsylvania and scientific director of the Abramson Family Cancer Research Institute. The study was published in Nature Cell Biology.

This kind of therapy is not something that has been tried before with liver cancer, Simon said. And in our models, so-called senolytic therapy greatly reduced disease burden, even in cases with advanced disease.

Loss of the enzyme FBP1 in human liver cells significantly increases tumor growth. Previous research has shown FBP1 levels are decreased in stage 1 tumors, and further reduced as the disease progresses. In this study, Simon and her team used RNA-sequencing data to identify FBP1 as universally under-expressed in the most common form of liver cancer, hepatocelluar carcinoma, regardless of underlying causes like obesity, alcoholism, and hepatitis.

The loss of FBP1 in liver cells activates the neighboring hepatic stellate cellswhich make up ten percent of liver masscausing fibrosis (tissue scarring) and subsequent stellate cell senescence, both of which promote tumor growth. Researchers found that these senescent stellate cells can be selectively targeted by senolytics, including Navitoclax (already in clinical trials for other diseases, like hematological malignancies), in order to blunt tumor progression driven by liver cell-specific FBP1 loss.

The team provides the first genetic evidence for FBP1 as a bona fide metabolic tumor suppressor in the liver and that its loss in liver cells promotes the growth of tumors because of effects on other cells within the tumor microenvironment.

Using genetically engineered mouse models, the team eliminated FBP1and found the disease progressed more rapidly and tumor burden greatly increased in carcinogen-mediated, dietary, and other forms of hepatocellular carcinoma.

The case with liver cancer is very dire, once you get beyond a certain stage there are limited, if any, treatments available, Simon said. As obesity rates continue to increase and viral infections continue to be a problem, there is going to be an increasing surge of liver cancer which currently has few treatment options. And since FBP1 activity is also lost in renal cancer,FBP1depletion may be generally applicable to a number of human cancers. Whats unique about our senotherapy approach is that we are specifically targeting other cells in the liver tumor environment rather than the cancer cells themselves.

Next steps, according to researchers will be to begin to test these treatments in a clinical setting. Additional Penn authors include Fuming Li, Peiwei Huangyang, Michelle Burrows, Kathy Guo, Romain Riscal, Jason Godfrey, Kyoung Eun Lee, Nan Lin, Pearl Lee, Ian A. Blair, and Brian Keith, as well as Bo Li, of Sun Yat-sen University. This work was supported by the National Key Research and Development Program (2016YFA0502600) of China and the National Cancer Institute (P01CA104838, R35CA197602 and P30CA016520).

Continued here:
New Liver Cancer Research Targets Non-Cancer Cells to Blunt Tumor Growth - Newswise

Cell Biology

Hamilton Thorne to Announce Q1 2020 Financial Results on May 28 and Hold Conference Call on May 29, 2020 – GlobeNewswire

BEVERLY, Mass. and TORONTO, May 26, 2020 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX-V: HTL), a leading provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART), research, and cell biology markets, today announced that it will release its financial results for the three-month period ended March 31, 2020 after market close on Thursday, May 28, 2020. The press release, with accompanying financial information, will be posted on the Companys website at http://www.hamiltonthorne.ltd and on http://www.sedar.com.

The Company will follow with a conference call on Friday, May 29, 2020 at 11:00 a.m. EDT to review highlights of the results. All interested parties are welcome to join the conference call by dialing toll free 1-855-223-7309 in North America, or 647-788-4929from other locations, and requesting Conference ID 29985315. A recording of the call will be available on Hamilton Thornes website shortly after the call.

About Hamilton Thorne Ltd. (www.hamiltonthorne.ltd)

Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART), research, and cell biology markets. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed, Planer, and Embryotech Laboratories brands, through its growing sales force and distributors worldwide. Hamilton Thornes customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.

Neither the TSX Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.

Read more:
Hamilton Thorne to Announce Q1 2020 Financial Results on May 28 and Hold Conference Call on May 29, 2020 - GlobeNewswire

Cell Biology

Powerful properties: how tobacco is being used to fight COVID-19 – Euronews

At the Institute for Plant Molecular and Cellular Biology in Valencia, a team of top scientists are attempting to harness the power of nature.

Using the latest techniques to cultivate and sequence the genome of the Nicotiana Benthamiana, a close relative of the tobacco plant, researchers taking part in the European funded Newcotiana project say they are able to produce tailor-made molecules to fight disease.

Native to Australia, the Nicotiana Benthamiana plant has been used to help produce vaccines and antibodies for viruses such as Ebola.

By injecting other DNA into its leaves, its genes can be modified to create specific pharmaceutical products in very large amounts.

"We give the plants instructions to improve them, to change specific genes. For example, we are interested in having plants that do not flower. We want to grow plants that produce more biomass, because those are the kinds of things we want the plant to do," says Marta Vzquez, a biotechnology research at IBMCP.

Hopes are high the technique, which harnesses the plant's cells and sap, could eventually help pave the way to producing a COVID-19 vaccine. Experts say the approach has several advantages. It can produce large amounts of the required protein, is low-cost compared to other methods and and is safe.

Plants are very useful for researchers as they are another mean of expressing viral proteins or nucleic acids without having to actually work with the causative virus itself. And we can use techniques of synthetic biology to make things like virus-like particles without handling the infectious virus, says George Lomonossoff, a virologist at the John Innes Centre.

The modified plant can generate proteins similar to those found in a human cell. Researchers say a growing number of companies are embracing this technique.

"There are about a hundred groups in the world that are trying to develop SARS COVID-2 vaccines. Some of these groups and private companies are using this plant, whose genome we have sequenced. Making the genome available...will help these firms optimise this production," insists Giovanni Giuliano, Research Director at Italys National Agency for New Technologies, ENEA.

By making the plants genome publicly available, scientists at the EU funded project hope it will speed up the search for new products that will fight both the current and future pandemics.

Here is the original post:
Powerful properties: how tobacco is being used to fight COVID-19 - Euronews

Cell Biology

May: glass frogs | News and features – University of Bristol

Glass frogs illustrate a new mechanism of camouflage: 'edge diffusion'. J Barnett

The frogs are always green but appear to brighten and darken depending on the background. J Barnett

Press release issued: 25 May 2020

Glass frogs are well known for their see-through skin but, until now, the reason for this curious feature has received no experimental attention.

A team of scientists from the University of Bristol, McMaster University, and Universidad de Las Amricas Quito, sought to establish the ecological importance of glass frog translucency and, in doing so, have revealed a novel form of camouflage.

Using a combination of behavioural trials in the field, computational visual modelling and a computer-based detection experiment, the study published in PNAS reveals that, while glass frog translucency does act as camouflage, the mechanism differs from that of true transparency.

Lead author, Dr James Barnett who began the research while a PhD student at the University of Bristol and is now based at McMaster University in Canada, said:

The frogs are always green but appear to brighten and darken depending on the background. This change in brightness makes the frogs a closer match to their immediate surroundings, which are predominantly made up of green leaves. We also found that the legs are more translucent than the body and so when the legs are held tucked to the frogs sides at rest, this creates a diffuse gradient from leaf colour to frog colour rather than a more salient sharp edge. This suggests a novel form of camouflage: edge diffusion.

Dr Barnett said scientific debate had often been skeptical of the degree to which glass frogs can be called transparent.

Transparency is, at face value, the perfect camouflage. It is relatively common in aquatic species where animal tissue shares a similar refractive index to the surrounding water. However, air and tissue are quite different in their refractive indices, so transparency is predicted to be less effective in terrestrial species. Indeed, terrestrial examples are rare. Although glass frogs are one commonly cited example of terrestrial transparency, their sparse green pigmentation means they are better described as translucent, said Dr Barnett.

Dr Barnetts PhD was supervised by Professor Nick Scott-Samuel, an expert in visual perception from the University of Bristols School of Psychological Sciences, and Innes Cuthill, Professor of Behavioural Ecology from Bristols School of Biological Sciences. Professor Scott-Samuel said:

Our study addresses a question that has been the topic of much speculation, both among the public and the scientific community. We now have good evidence that the frogs glass-like appearance is, indeed, a form of camouflage.

Professor Cuthill said: Animal camouflage has long been a textbook example of the power of Darwinian natural selection. However, in truth, we are only beginning to unravel how different forms of camouflage actually work. Glass frogs illustrate a new mechanism that we hadnt really considered before.

Paper:

Imperfect transparency and camouflage in glass frogs by J. Barnett et al in PNAS.

School of Biological Sciences

Research in the School of Biological Sciences spans the full range of biological disciplines, from genomics and cell biology, through diverse aspects of whole organism biology and evolution, to population biology and ecosystem services.

Our research is organised around four main themes that reflect our strengths and interests: Evolutionary Biology; Animal Behaviour and Sensory Biology; Plant and Agricultural Sciences; and Ecology and Environmental Change.

Animal behaviour and sensory biology:

Our research is aimed at understanding the adaptive significance of behaviour, from underlying mechanisms (how, or proximate, questions) through evolutionary explanations of function (why, or ultimate, questions) to interspecific interactions at the community level.

The approach is strongly interdisciplinary, using diverse physiological, biomechanical, neurological and molecular techniques, theoretical modelling and behavioural experiments in both laboratory and natural populations to link from the genetic foundations through to the evolution of behaviour and sensory systems.

Our study systems range from bats to birds and bees, mongooses to moths, fish to flies, and dolphins to decapods.

School of Pyschological Sciences

The School of Psychological Science is a vibrant, friendly, and exciting place to work and study in. We offer accredited undergraduate and postgraduate taught courses, and have a lively and productive community of PhD students and research staff.

Our students benefit from being taught and supervised in an intellectually rich environment by staff who are working at the forefront of the discipline. Members of the School have won a number of awards for their research, highlighting their contribution to Psychology nationally and internationally.

Our research spans developmental, social, cognitive and biological psychology, neuropsychology, and vision science. It has applications in areas ranging from human performance, memory, and communication to addiction and neurological disease.

Read the rest here:
May: glass frogs | News and features - University of Bristol